Brucellosis is a zoonotic infection and systemic disease in humans and a wide range of animals. The causative agents are the bacteria of the genus Brucella, which are spread throughout the world (
1,
2). Brucellae are gram-negative and non-motile bacteria, capable of intracellular growth. Brucellosis involves a large scale of organs in humans, which are associated with diverse and non-specific clinical signs and lead to numerous complaints from patients, such as drowsiness and anorexia, malaise, excessive sweating, weight loss, back pain or arthritis and depression. Sometimes physical findings, especially fever and lymphadenopathy, mild hepatomegaly and splenomegaly are reported in patients and these nonspecific symptoms make clinical diagnosis difficult. Accurate diagnosis requires paraclinical approaches. Diagnostic methods of brucellosis are usually based on detecting specific antibodies in the patient’s serum. Nowadays many serological tests are applied for the diagnosis of human brucellosis (
3,
4), Most routine tests are serum agglutination tests based on Wright and 2-Mercaptoethanol (2-ME), which were developed in 1897 by Weight et al. (
5) and nowadays they are still used as reference tests in clinical laboratories. Other tests, which were developed later, include Rose Bengal, complement fixation, indirect coombs and the Enzyme Linked Immunosorbent Assay (ELISA) (
6). Rose Bengal Test (RBT) is a simple screening test used in endemic areas, which may also lead to false-positive results. Therefore, in these regions Serum Agglutination Tests (SAT) are used to reduce false-positive results caused by Rose Bengal (
7,
8). Agglutination test titers in most patients with acute brucellosis showed 1/320 or more at the end of the second week of disease, where in 20% of patients these titers remain significantly high after one year of treatment. Higher levels of agglutinin titer for Brucella have been reported in patients with
Francisella tularensis and
Yersinia enterocolitica, and in patients who have recently received a vaccination of cholera or have been tested by the Brucella skin test. The ELISA test is highly capable of tracking IgG and IgM cross-reacting antibodies (
9).